Drugs / FLUAD-H5N1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00841763 | Oct 2008 → Apr 2009 | influenza | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00434733 | Jan 2007 → ? | influenza | Novartis | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLUAD-H5N1 | “Evaluate the safety, tolerability and immunogenicity of two doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted With MF59 (Fluad-H5N1) in Adult and Elderly Subjects” NCT00841763 ↗1“Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects” NCT00434733 ↗ |
| Modality | Vaccine | “FLUAD-H5N1 Influenza Vaccine” NCT00434733 ↗ |
| Route | Intramuscular | “Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.” NCT00841763 ↗ |